A detailed history of Roble, Belko & Company, Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 4,456 shares of ABBV stock, worth $788,489. This represents 0.14% of its overall portfolio holdings.

Number of Shares
4,456
Previous 4,429 0.61%
Holding current value
$788,489
Previous $760,000 15.79%
% of portfolio
0.14%
Previous 0.13%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$163.84 - $199.33 $4,423 - $5,381
27 Added 0.61%
4,456 $880,000
Q1 2024

Apr 11, 2024

BUY
$159.82 - $182.1 $613,229 - $698,717
3,837 Added 648.14%
4,429 $807,000
Q4 2023

Feb 01, 2024

BUY
$137.6 - $154.97 $25,593 - $28,824
186 Added 45.81%
592 $92,000
Q3 2023

Nov 01, 2023

SELL
$133.59 - $154.65 $4,942 - $5,722
-37 Reduced 8.35%
406 $61,000
Q1 2023

May 10, 2023

SELL
$144.61 - $166.54 $4,482 - $5,162
-31 Reduced 6.54%
443 $71,000
Q2 2022

Aug 10, 2022

SELL
$137.62 - $174.96 $9,633 - $12,247
-70 Reduced 12.87%
474 $73,000
Q1 2022

May 06, 2022

BUY
$131.98 - $163.75 $3,695 - $4,585
28 Added 5.43%
544 $88,000
Q4 2021

Feb 07, 2022

BUY
$107.43 - $135.93 $7,520 - $9,515
70 Added 15.7%
516 $70,000
Q3 2021

Nov 03, 2021

BUY
$106.4 - $120.78 $3,298 - $3,744
31 Added 7.47%
446 $48,000
Q3 2020

Nov 10, 2020

BUY
$85.91 - $100.83 $14,776 - $17,342
172 Added 70.78%
415 $36,000
Q2 2020

Aug 10, 2020

SELL
$73.37 - $98.18 $141,604 - $189,487
-1,930 Reduced 88.82%
243 $24,000
Q4 2019

Jan 13, 2020

SELL
$72.13 - $90.25 $49,553 - $62,001
-687 Reduced 24.02%
2,173 $192,000
Q3 2019

Nov 13, 2019

BUY
$62.98 - $75.72 $164,818 - $198,159
2,617 Added 1076.95%
2,860 $217,000
Q3 2017

Nov 08, 2017

BUY
$69.85 - $89.22 $16,973 - $21,680
243
243 $22,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $313B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Roble, Belko & Company, Inc Portfolio

Follow Roble, Belko & Company, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Roble, Belko & Company, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Roble, Belko & Company, Inc with notifications on news.